30 recruiting. 30 Phase 2, 5 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 30 | Recruiting 30 |
| Phase 1 | 5 | Recruiting 5 |
| Phase 3 | 3 | Recruiting 3 |
Follow Schizophrenia: new trials by email Literature Review of Schizophrenia trials Research Report on Schizophrenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in Schizophrenia Deferiprone (DFP), N-Acetyl Cysteine (NAC) - Schizoaffecitve Disorder, Schizophrenia and Schizoaffective Disorder | Phase 2 | Recruiting | Amit Lotan | 80 | 2026-08-12 | 2026-09-29 |
| Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia Ublituximab - Schizophrenia | Phase 2 | Recruiting | TG Therapeutics, Inc. | 60 | 2026-07-27 | 2026-10-30 |
| No Guts No Glory Probiotics Probiotic Formula, Placebo - Patients Using Olanzapine, Quetiapine, Risperidone or Clozapine | Phase 2 / Phase 3 | Recruiting | University Medical Center Groningen | 112 | 2026-06-01 | 2026-05-26 |
| A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia ML-007C-MA - Schizophrenia | Phase 2 | Recruiting | MapLight Therapeutics | 500 | 2026-03-31 | 2026-10-15 |
| Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia GXV813, Placebo - Schizophrenia | Phase 2 | Recruiting | Novartis Pharmaceuticals | 142 | 2026-03-16 | 2026-07-29 |
| Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia NBI-1117570, Placebo - Schizophrenia | Phase 2 | Recruiting | Neurocrine Biosciences | 120 | 2026-02-16 | 2026-07-22 |
| A Study of Brenipatide in Adult Participants With Schizophrenia Brenipatide, Placebo - Schizophrenia | Phase 2 | Recruiting | Eli Lilly and Company | 450 | 2026-02-10 | 2026-10-07 |
| Sex Differences in NMDA-enhancing Treatment of Schizophrenia NMDAE, Placebo Cap - Schizophrenia | Phase 2 | Recruiting | China Medical University Hospital | 90 | 2025-09-16 | 2025-09-17 |
| A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia Emraclidine, Placebo - Schizophrenia | Phase 2 | Recruiting | AbbVie | 268 | 2025-08-04 | 2026-09-15 |
| Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine Cariprazine Depot, Cariprazine Depot MTD, Oral Cariprazine 3 mg/day - Schizophrenia, Bipolar I Disorder | Phase 1 / Phase 2 | Recruiting | Mapi Pharma Ltd. | 24 | 2025-08-01 | 2026-05-01 |
| A Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia BR5402A, BR5402A-1, BR5402B - Schizophrenia | Phase 2 | Recruiting | Boryung Pharmaceutical Co., Ltd | 120 | 2025-05-30 | 2025-09-15 |
| Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder Tirzepatide, Placebo - Alcohol Use Disorder, Alcohol Abuse/Dependence | Phase 2 | Recruiting | Anders Fink-Jensen, MD, DMSci | 108 | 2025-05-05 | 2026-02-10 |
| Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness Transcranial magnetic stimulation - Major Depressive Disorder, Obsessive-Compulsive Disorder | Phase 2 | Recruiting | Brigham and Women's Hospital | 180 | 2025-01-30 | 2026-07-16 |
| Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia S1RA plus NMDAE, S1RA plus Placebo Cap - Schizophrenia | Phase 2 | Recruiting | China Medical University Hospital | 90 | 2024-09-23 | 2026-03-24 |
| Tolerability of MDMA in Schizophrenia MDMA 40mg, MDMA 80mg, MDMA 120mg - Schizophrenia | Phase 1 / Phase 2 | Recruiting | Anya Bershad, MD, PhD | 20 | 2024-09-01 | 2026-07-17 |
| Study of ALTO-101 in Patients With Schizophrenia ALTO-101, ALTO-101 Transdermal Delivery System, Placebo - Schizophrenia, Cognitive Impairment | Phase 2 | Recruiting | Alto Neuroscience | 82 | 2024-06-11 | 2025-12-26 |
| MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction MitoQ, Placebo - Schizophrenia and Related Disorders, Mitochondrial Alteration | Phase 2 / Phase 3 | Recruiting | Mclean Hospital | 100 | 2024-06-01 | 2025-09-25 |
| Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia Placebo, Buprenorphine 0.15 MG [Belbuca] - Schizophrenia | Phase 2 | Recruiting | University of California, Los Angeles | 40 | 2024-05-17 | 2026-04-28 |
| NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia NMDAE, Placebo Cap - Schizophrenia | Phase 2 | Recruiting | China Medical University Hospital | 90 | 2023-10-12 | 2026-10-23 |
| Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia NMDAE plus AIFA, NMDAE plus Placebo Cap - Schizophrenia | Phase 2 | Recruiting | China Medical University Hospital | 80 | 2022-02-23 | 2026-03-24 |
Showing 20 of 30. Sign in to see all of them.
Psychotic Disorders (8) · Cognitive Dysfunction (2) · Depressive Disorder, Major (2) · Inflammation (2) · Mental Disorders (2) · Schizophrenia, Treatment-Resistant (2) · Alcoholism (1) · Anxiety Disorders (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Depression (1) · Generalized Anxiety Disorder (1) · Metabolic Syndrome (1) · Mood Disorders (1)
Schizophrenia Spectrum and Other Psychotic Disorders (29) · Mental Disorders (28) · Pathological Conditions, Signs and Symptoms (4) · Cognition Disorders (2) · Depressive Disorder (2) · Neurocognitive Disorders (2) · Pathologic Processes (2) · Signs and Symptoms (2) · Alcohol-Related Disorders (1) · Behavior (1) · Behavioral Symptoms (1) · Body Weight (1) · Body Weight Changes (1) · Chemically-Induced Disorders (1) · Glucose Metabolism Disorders (1)
Acetazolamide (1) · Acetylcysteine (1) · Buprenorphine (1) · Cromolyn Sodium (1) · Deferiprone (1) · Electrocardiography (1) · N-Methyl-3,4-methylenedioxyamphetamine (1) · Restraint, Physical (1) · Sodium Chloride (1) · Sugars (1) · Tirzepatide (1) · Transcranial Magnetic Stimulation (1) · cariprazine (1) · mitoquinone (1) · ublituximab (1)
China Medical University Hospital (8) · Vishwajit Nimgaonkar, MD PhD (2) · AbbVie (1) · Alto Neuroscience (1) · Amit Lotan (1) · Anders Fink-Jensen, MD, DMSci (1) · Anya Bershad, MD, PhD (1) · Boryung Pharmaceutical Co., Ltd (1) · Brigham and Women's Hospital (1) · Eli Lilly and Company (1) · MapLight Therapeutics (1) · Mapi Pharma Ltd. (1) · Mclean Hospital (1) · National Cheng-Kung University Hospital (1) · Neurocrine Biosciences (1)
United States (15) · Taiwan (10) · India (3) · Bulgaria (2) · Israel (2) · Argentina (1) · Brazil (1) · China (1) · Denmark (1) · Japan (1) · Netherlands (1) · Romania (1) · South Korea (1) · Switzerland (1) · United Kingdom (1)
Anders Fink-Jensen, MD, DMSc, Professor (1) · Dost Ongur, MD, PhD (1) · Faith Dickerson, PhD, MPH (1) · Iris E.C. Sommer, Prof. Dr. (1) · Joseph C Masdeu, MD, PhD (1) · Shan H Siddiqi, MD (1) · Vishwajit L Nimgaonkar, M.D., Ph.D. (1) · Vishwajit L. Nimgaonkar, M.D., Ph.D. (1) · Yen-Kuang Yang, Dr (1)
1DP5OD036172-01 (1), 2025 (1)